A Phase 2 interventional study of YA-101 and Placebo in Multiple System Atrophy, sponsored by Dasher Neuroscience Inc.. Active, not recruiting at 9 sites in 3 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Dasher Neuroscience Inc. · Phase 2, Interventional, and Treatment
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
The purpose of the study is to evaluate 2 doses of YA-101 compared to placebo in MSA patients, including: 1) safety and tolerability, 2) pharmacokinetics, and 3) potential efficacy of YA-101.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
This study's planned enrollment of 75 is above the median of 40 across 131 interventional studies indexed under Multiple System Atrophy.
Browse Multiple System Atrophy studies →This is the only study on the registry with Dasher Neuroscience Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: YA-101
Drug: Placebo
Drug: YA-101 • YA-101 taken BID
Placebo taken BID
Incidence and severity of Adverse Events (AEs)
Incidence and severity of Adverse Events (AEs).
Time frame: Baseline to Day 112
Maximum observed concentration (Cmax)
To describe the pharmacokinetics parameter (Cmax) of YA-101 using sparse PK sampling.
Time frame: Baseline to Day 84
Area under the concentration-time curve (AUC)
To describe the pharmacokinetics parameter (AUC) of YA-101 using sparse PK sampling.
Time frame: Baseline to Day 84
Time of maximum observed concentration (Tmax)
To describe the pharmacokinetics parameter (Tmax) of YA-101 using sparse PK sampling.
Time frame: Baseline to Day 84
Change from baseline in Unified Multiple System Atrophy Rating Scale (UMSARS) over time
The unified multiple system atrophy rating scale (UMSARS) is composed of four subscales: UMSARS-I (12 items) rates patient-reported functional disability, UMSARS-II (14 items) assesses motor impairment based on a clinical examination, UMSARS-III records blood pressure and heart rate in the supine and standing positions, and UMSARS-IV (1 item) rates chore-based disability. Higher scores on the UMSARS indicate greater disability.
Time frame: Baseline to Day 112
Change from baseline in the 10-meter walking test
Time frame: Baseline to Day 112
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.